Clinical trials: Neoadjuvant Treatment
Locally Advanced Rectal Adenocarcinoma
Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old
The primary objective of the NACRE-2 trial is to assess whether the addition of chemotherapy after short-course radiotherapy is more effective than short-course radiotherapy alone in elderly patients with locally advanced rectal…
- Trial name
- NACRE-2 (NCT07118800)
- Testing
- FOLFOX4s, Short Course Radiotherapy
- Volunteers
- 160 people
- Sponsor
- UNICANCER
Locally Advanced Rectal Cancer
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
This is a multicenter, prospective, randomized controlled study to evaluate the effectiveness and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and PCSK9 inhibitor in the treatment of patients with pMMR/MSS…
- Trial name
- NCT06304987
- Testing
- Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor, Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Beijing Friendship Hospital
Individualized Chemotherapy
Breast Cancer Treated by Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy, known as "first" or "induction chemotherapy" in the therapeutic assumption of breast cancer is based on the narrow dependence preclinically revealed between primary tumour, tumoral angiogenesis and…
- Trial name
- NCT00425516
- Testing
- Taxotere, 5-Fluorouracil, Epirubicin
- Where
- 6 sites in France
- Volunteers
- 264 people
- Sponsor
- Centre Jean Perrin
Hepatocellular Carcinoma
Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative
Percutaneous ablation (PA) is the only non-surgical curative treatment of hepatocellular carcinoma (HCC). Due to its excellent tolerance, particularly in patients with portal hypertension or bearing comorbidities, it now…
- Trial name
- LENVABLA (NCT05113186)
- Testing
- Lenvatinib Pill
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ovarian Neoplasms, Fallopian Tube Neoplasms
OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206
A feasibility study of neoadjuvant chemotherapy (NAC) followed by interval cytoreductive surgery (ICS) and postoperative chemotherapy for stage III/IV mullerian carcinomas such as ovarian, tubal and peritoneal carcinomas.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00112086
- Testing
- Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Japan Clinical Oncology Group
Melanoma
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Randomized trial to determine if neo-adjuvant subcutaneous GM-CSF restores the host regional lymph node immunity
- Trial name
- NCT02451488
- Testing
- GM-CSF, Standard of Care
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Breast Cancer
Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Estrogen can stimulate the growth of breast cancer cells.
- Trial name
- NCT00963729
- Testing
- cyclophosphamide, docetaxel, epirubicin hydrochloride
- Where
- 5 sites in South Korea, United Kingdom
- Volunteers
- 756 people
- Sponsor
- Imperial College London
Prostate Cancer (Adenocarcinoma)
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery.
- Trial name
- NCT07907653
- Testing
- Deutenzalutamide, Docetaxel, ADT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-small Cell Lung Cancer
Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy
This is a prospective, single arm, single center clinical study to determine the efficacy and safety of pablizumab combined with apatinib and neoadjuvant chemotherapy in patients with stage iia-iiia non-small cell lung cancer.
- Trial name
- NCT04968002
- Testing
- pablizumab combined with apatinib and neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ulcerative Colitis
Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis
A study to investigate the safety and efficacy of TLL018 compared with placebo in subjects with moderate to severe ulcerative colitis.
- Trial name
- NCT05121402
- Testing
- TLL018
- Where
- United States
- Sponsor
- TLL Pharmaceutical, LLC
Radiotherapy, Radiation-Induced Complications
A Prospective, Single-Arm Clinical Study of a Dietary Supplement for the Prevention of Acute Radiation-Induced Rectal Injury During Neoadjuvant Chemoradiotherapy for Rectal Cancer
This clinical study is a prospective, single-arm, single-center trial aimed at assessing the safety and efficacy of tributyrin (TB) as a dietary supplement for preventing acute radiation-induced rectal injury (ARII).
- Trial name
- NCT07802002
- Testing
- Tributyrin
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Breast Cancer
The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer
Some studies have demonstrated the efficacy of Abraxane in treating breast cancer in both adjuvant and metastatic settings. Few data is available on Abraxane in neoadjuvant treatment for breast cancer.
- Trial name
- NCT03647280
- Testing
- Abraxane, Epirubicin
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Stage II Breast Cancer, Stage III Breast Cancer
Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer
Molecular expression in breast cancer (BC) defines special fenotypes with different prognostic and predictive features.Since the addition of trastuzumab and lapatinib to chemotherapy, HER2 overexpressing tumors have become the…
- Trial name
- NCT01431196
- Testing
- Autologous dendritic cell vaccination
- Where
- Spain
- Volunteers
- 29 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Colorectal Cancer, Neoadjuvant Therapy
Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
Apatinib has been proved to be effective and safe among patients in advanced colorectal cancer in several trials. the investigators aimed to evaluate its efficacy and safety as the neoadjuvant therapy in real world practice, and…
- Trial name
- NCT03377842
- Testing
- FOLFOX regimen, apatinib and FOLFOX regimen
- Volunteers
- 100 people
- Sponsor
- Sichuan Provincial People's Hospital
Adenocarcinoma of the Pancreas, Pancreas Cancer
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
Standard treatment for newly diagnosed operable pancreatic cancer usually involves undergoing surgery first and then receiving chemotherapy with or without radiation therapy.
- Trial name
- NCT03778879
- Testing
- CCX872-B
- Where
- United States
- Sponsor
- Alan Katz
Locally Advanced Hepatocellular Carcinoma
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
The proposed study is an open-label, single institution, single arm phase 1b study of neoadjuvant cabozantinib plus nivolumab in patients with locally advanced HCC.
- Trial name
- NCT03299946
- Testing
- Cabozantinib, Nivolumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Neoplasms, Breast Cancer
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Trial name
- NCT05113251
- Testing
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab
- Where
- 145 sites in United States, Brazil and 16 more
- Volunteers
- 927 people
- Sponsor
- AstraZeneca
PFS, OS
Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer
To clarify the potential benefits of NACT before radical surgery(RS), we perform a phase III, randomised controlled trial to compare NACT plus RS with RS alone in patients with stages IB2 and IIA2 cervical cancer.
- Conditions
- PFS, OS, Quality of Life
- Trial name
- SYSGO-003 (NCT02629718)
- Testing
- NACT (Paclitaxel + Cisplatin or carboplatin), radical surgery
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Neoadjuvant Chemotherapy
Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug Sensitivity or Physician's Choice
Neoadjuvant chemotherapy is an important treatment for breast cancer patients. Patients with triple negative or Her2 enriched subtype who achieved pCR after neoadjuvant chemotherapy would have longer survival.
- Conditions
- Breast Cancer, Neoadjuvant Chemotherapy, Drug Effect
- Trial name
- NCT04130750
- Testing
- treatment of drug screening
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
2-year Disease-Free Survival
Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients
The purpose of this study is to evaluate the efficiency and safety of Gefitinib Neoadjuvant Therapy and Oral Navelbine Carboplatin Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢA NSCLC patients with EGFR mutation.
- Trial name
- NCT03203590
- Testing
- Oral Navelbine + Carboplatin, Gefitinib
- Where
- 5 sites in China
- Volunteers
- 590 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.